Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses | Psychedelic Invest

– Company speakers include Doug Drysdale, Chief Executive Officer; and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer – – Featured key opinion leaders include Dr. Maurizio Fava, M.D., Massachusetts General Hospital and Harvard Medical School; and Dr. Gitte Moos Knudsen, Professor, Chief Neurologist, DMSc, Neurobiology Research Unit, Rigshospitalet and University of Copenhagen, Denmark…

Ionis, Otsuka sign agreement for hereditary angioedema therapy

Share this article Ionis will be responsible for the non-clinical and clinical development of the product. Credit: Mongkolchon Akesin / Shutterstock.com. Ionis Pharmaceuticals has signed

December 19, 2023

Arda secures $43m funding to develop cell depletion therapies

The company’s single-cell-based discovery engine can detect the specific pathogenic cells that cause disease, and their surface markers. Credit: PeopleImages.com – Yuri A/Shutterstock. Arda Therapeutics

October 10, 2024

AliveCor gets FDA nod for portable 12-lead, AI-powered ECG device

AliveCor has spent years battling with Apple over the market for consumer heart monitoring technology. Now it’s hoping to make its imprint on professional health

June 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.